Skip to content
DraconiticResearch
Search Sources API
197,788 studies31 sourcesUpdated 17 min ago
Peer-reviewedCC BYBiomedicines

Bivalent CD47 Immunotoxin for Targeted Therapy of Lung Cancer

  • Jihong Ma1
  • Dinoop Ravindran Menon2
  • Zhaohui Wang1
  • Danielle Mintzlaff1
  • Hugh Rock2
  • Lauren Giesy2
  • Christene A. Huang1
  • David W. Mathes1
  • Trevor Nydam3
  • Elizabeth A. Pomfret3
  • D. Ross Camidge2
  • Hatim E. Sabaawy2
2 more authors
  • Sharon R. Pine2
  • Zhirui Wang1
  1. 1Division of Plastic and Reconstructive Surgery, Department of Surgery, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
  2. 2Division of Medical Oncology, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
  3. 3Division of Transplant Surgery, Department of Surgery, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
Read full textPDFCite

Related

  1. Pre-Treatment CD44 and CD47 Expression and Pathological Complete Response After Neoadjuvant Therapy in Breast Cancer: An Exploratory Single-Center Study
    Hatice Asoglu, Esra Asarkaya, Abdurrahman Aykut +13
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0OncologyCrossref
  2. Periprocedural Wound Complication Risks in Cancer Pain Patients Following Targeted Cancer Therapy: A Retrospective Analysis
    Soun Sheen, Vishal Bansal, Xiaowen Sun +2
    Cancer reports (Hoboken, N.J.)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Enhancing intravesical bladder cancer therapy: from mucoadhesive to targeted drug delivery strategies
    Hatixhe Sahini, Maria Anzengruber, Ulrich Lächelt
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Efficacy and safety of neoadjuvant targeted therapy in surgically treated patients with ALK-rearranged non-small cell lung cancer
    Yudong Liu, Li Fang, Zhongjing Jiang +3
    Journal of thoracic diseasePeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  5. PINK1-mediated mitophagy supports lung cancer initiation and limits the efficacy of KRAS -targeted therapy
    Diogo Gonçalves, Emma Guilbaud, Léa Di Mascio +16
    Science AdvancesPeer-reviewedCC BYFull textEpidemiology & public healthCrossrefEurope PMC

Cite

BibTeXRIS
BibTeX
@article{ma2026bivalent,
  title = {{Bivalent CD47 Immunotoxin for Targeted Therapy of Lung Cancer}},
  author = {Jihong Ma and Dinoop Ravindran Menon and Zhaohui Wang and Danielle Mintzlaff and Hugh Rock and Lauren Giesy and Christene A. Huang and David W. Mathes and Trevor Nydam and Elizabeth A. Pomfret and D. Ross Camidge and Hatim E. Sabaawy and Sharon R. Pine and Zhirui Wang},
  journal = {Biomedicines},
  year = {2026},
  month = sep,
  url = {https://europepmc.org/article/PMC/PMC13701539},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Bivalent CD47 Immunotoxin for Targeted Therapy of Lung Cancer
AU  - Jihong Ma
AU  - Dinoop Ravindran Menon
AU  - Zhaohui Wang
AU  - Danielle Mintzlaff
AU  - Hugh Rock
AU  - Lauren Giesy
AU  - Christene A. Huang
AU  - David W. Mathes
AU  - Trevor Nydam
AU  - Elizabeth A. Pomfret
AU  - D. Ross Camidge
AU  - Hatim E. Sabaawy
AU  - Sharon R. Pine
AU  - Zhirui Wang
PY  - 2026
DA  - 2026/09/26
JO  - Biomedicines
UR  - https://europepmc.org/article/PMC/PMC13701539
SN  - 2227-9059
ER  -